Drug Trial Radar · NCT07938463
Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Apr 30, 2027
Primary completion
Nov 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Tango Therapeutics, Inc.; ALK Positive / ALK Positive Patients Association
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TAP-ALK is a DF/HCC investigator-sponsored interventional study of TNG462 (vopimetostat) in combination with lorlatinib for participants with MTAP-deleted, ALK-rearranged non-small cell lung cancer (NSCLC) following progression on prior tyrosine kinase inhibitor (TKI) therapy. The study is being conducted under IND 183798 and plans to enroll 30 participants.
Conditions
- ALK Positive Non-small Cell Lung Cancer
Interventions
TNG462 vopimetostatDrug
Investigational drug Supplier/manufacturer: Tango Therapeutics
LorlatinibDrug
Source/manufacturer: Commercial supply / Pfizer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience Dose-Limiting Toxicity (DLT)Time frame: Up to 28 days.
- Maximum Tolerated Dose (MTD) of TNG462Time frame: Up to 28 days.
- MTD of LorlatinibTime frame: Up to 28 days.
- Recommended Phase II Dose (RP2D) of TNG462 in Combination with LorlatinibTime frame: Up to 28 days.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.